New Delhi, Aug 1
The phase III clinical trial for India’s 1st dengue vaccine has enroled 70 per cent participants, said Union Minister of State for Health, Prataprao Jadhav, in the Parliament on Friday.
In a written reply to the Lok Sabha, Jadhav shared details on the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll.
“The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed,” Jadhav said. The trial is likely to be completed by October.
“The trial has been implemented in 20 sites across India. The approximate budget is Rs 1.3 to 1.5 crore per site for the trial,” he added.
The indigenous tetravalent dengue vaccine, DengiAll, is being developed by Panacea Biotec under a licensing agreement with the National Institutes of Health (NIH). The vaccine targets all four dengue virus subtypes and has shown promising results in earlier clinical trials.
As per data from the National Centre for Disease Control (NCDC), a total of 5,73,563 laboratory-confirmed (L form) dengue cases were reported in 2024.